Article
Opposite Modulation of RAC1 by Mutations in TRIO Is Associated with Distinct, Domain-Specific Neurodevelopmental Disorders.
American journal of human genetics - 5 Mar 2020
Barbosa Sónia, Greville-Heygate Stephanie, Bonnet Maxime, Godwin Annie, Fagotto-Kaufmann Christine, Kajava Andrey V, Laouteouet Damien, Mawby Rebecca, Wai Htoo Aung, Dingemans Alexander J M, Hehir-Kwa Jayne, Willems Marjorlaine, Capri Yline, Mehta Sarju G, Cox Helen, Goudie David, Vansenne Fleur, Turnpenny Peter, Vincent Marie, Cogné Benjamin, Lesca Gaëtan, Hertecant Jozef, Rodriguez Diana, Keren Boris, Burglen Lydie, Gérard Marion, Putoux Audrey, Cantagrel Vincent, Siquier-Pernet Karine, Rio Marlene, Banka Siddharth, Sarkar Ajoy, Steeves Marcie, Parker Michael, Clement Emma, Moutton Sébastien, Tran Mau-Them Frédéric, Piton Amélie, de Vries Bert B A, Guille Matthew, Debant Anne, Schmidt Susanne, Baralle Diana
Abstract excerpt
The Rho-guanine nucleotide exchange factor (RhoGEF) TRIO acts as a key regulator of neuronal migration, axonal outgrowth, axon guidance, and synaptogenesis by activating the GTPase RAC1 and modulating actin cytoskeleton remodeling. Pathogenic variants in TRIO are associated with neurodevelopmental diseases, including intellectual disability (ID) and autism spectrum disorders (ASD). Here, we report the largest...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
